<DOC>
	<DOCNO>NCT01022060</DOCNO>
	<brief_summary>The purpose study determine whether Renalof administration promote partial total dissolution urinary calculus improve physicochemical parameter metabolic activity patient recurrent calcic urolithiasis . The duration double-blind placebo control phase 3 clinical trial 12 week . The estimated number patient recruit randomized study 110 . Ultrasonographic humoral parameter assess every 4 week .</brief_summary>
	<brief_title>Renalof Dissolution Renal Calculi Patients With Recurrent Calcic Lithiasis</brief_title>
	<detailed_description />
	<mesh_term>Calculi</mesh_term>
	<mesh_term>Urolithiasis</mesh_term>
	<mesh_term>Kidney Calculi</mesh_term>
	<mesh_term>Nephrolithiasis</mesh_term>
	<mesh_term>Lithiasis</mesh_term>
	<criteria>Idiopathic calcic lithiasis Calculus size lesser equal 2.0 cm ( 0.79 inch ) Signed informed consent Calculus size great 2,0 cm ( 0.79 inch ) Pregnancy Malignant neoplastic condition Previous treatment destruction calculus urinary tract</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Dietary supplement</keyword>
	<keyword>Renalof</keyword>
	<keyword>Recurrent calcic urolithiasis</keyword>
	<keyword>Renal calculus</keyword>
</DOC>